David T. Dexter, Ph.D.

Affiliations: 
Brain sciences, Medicine Imperial College, London, London, England, United Kingdom 
Area:
Neurodegeneration, iron metabolism, neuroinflammation
Website:
http://www1.imperial.ac.uk/medicine/people/d.dexter/
Google:
"David Dexter"
Mean distance: 26716.5
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Al-Zaid FS, Hurley MJ, Dexter DT, et al. (2023) Neuroprotective role for RORA in Parkinson's disease revealed by analysis of post-mortem brain and a dopaminergic cell line. Npj Parkinson's Disease. 9: 119
Lewis FW, Fairooz S, Elson JL, et al. (2020) Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease. Archives of Toxicology
Sharma PK, Wells L, Rizzo G, et al. (2020) DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics
Gonzalez-Carter D, Goode AE, Kiryushko D, et al. (2019) Quantification of blood-brain barrier transport and neuronal toxicity of unlabelled multiwalled carbon nanotubes as a function of surface charge. Nanoscale
Harrison IF, Powell NM, Dexter DT. (2018) The Histone Deacetylase Inhibitor Nicotinamide Exacerbates Neurodegeneration in the Lactacystin Rat Model of Parkinson's Disease. Journal of Neurochemistry
Gonzalez-Carter D, Ong ZY, McGilvery CM, et al. (2018) L-DOPA functionalized, multi-branched gold nanoparticles as brain-targeted Nano-vehicles. Nanomedicine : Nanotechnology, Biology, and Medicine
Pankratova S, Klingelhofer J, Dmytriyeva O, et al. (2018) The S100A4 Protein Signals through the ErbB4 Receptor to Promote Neuronal Survival. Theranostics. 8: 3977-3990
Moreau C, Duce JA, Rascol O, et al. (2018) Iron as a therapeutic target for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society
Harrison IF, Smith AD, Dexter DT. (2017) Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition. Neuroscience Letters. 666: 48-57
Martin-Bastida A, Ward RJ, Newbould R, et al. (2017) Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. Scientific Reports. 7: 1398
See more...